Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-196.04	-76.42	-143.1	-165.29	-124.09
Depreciation & Amortization	0.3	0.34	0.53	0.62	0.79
Other Amortization	10.55	6.37	0.81	0.81	0.78
Asset Writedown & Restructuring Costs	-	-	-	-	7.36
Loss (Gain) From Sale of Investments	-0.41	-2.5	-4.1	-0.83	1.56
Stock-Based Compensation	14.05	18.43	21.71	35.4	29.78
Other Operating Activities	67.92	-73.39	-	-0.28	-0.11
Change in Accounts Receivable	4.59	-3.8	20.12	-5.08	-9.62
Change in Inventory	0.7	-1.7	1.18	-0.12	-1.46
Change in Accounts Payable	-1.1	1.98	0.35	1.17	-2.85
Change in Other Net Operating Assets	24.09	3.21	9.77	-15.96	-9.26
Operating Cash Flow	-75.37	-127.49	-92.72	-149.55	-107.12
Capital Expenditures	-	-0.14	-	-0.12	-0.21
Sale (Purchase) of Intangibles	-	-	-	-	-5.5
Investment in Securities	43.38	95.62	7.94	-104.14	147.55
Investing Cash Flow	43.38	95.47	7.94	-104.26	141.84
Long-Term Debt Issued	27.25	83.3	-	-	-
Long-Term Debt Repaid	-0.25	-	-	-	-
Net Debt Issued (Repaid)	27	83.3	-	-	-
Issuance of Common Stock	9.51	1.45	1.12	193.74	13.65
Other Financing Activities	-6.46	-43.11	-	-	60
Financing Cash Flow	30.05	41.65	1.12	193.74	73.65
Foreign Exchange Rate Adjustments	0.02	-0.01	-0.03	-0.49	-0.05
Net Cash Flow	-1.92	9.62	-83.69	-60.56	108.32
Free Cash Flow	-75.37	-127.63	-92.72	-149.67	-107.33
Free Cash Flow Margin	-51.60%	-87.88%	-63.50%	-95.29%	-51.15%
Free Cash Flow Per Share	-6.89	-15.10	-12.18	-27.42	-21.40
Cash Interest Paid	14.38	38.6	21.23	34.45	15.54
Levered Free Cash Flow	-49.43	-77.09	-39.95	-101.35	-58.64
Unlevered Free Cash Flow	-31.32	-60.07	-25.87	-86.54	-43.14
Change in Working Capital	28.27	-0.3	31.42	-19.99	-23.19

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q